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Background: Endothelial microparticles (EMPs) can be involved in inﬂammatory process, blood coagulation, and
regulation of vascular function. However, it remains unclear whether EMPs participate in the pathogenesis of
ACS. The purpose of this study is to investigate the impact of EMPs on Th1/Th2 development and functions
in vitro.
Methods: Eight-ﬁve patients were allocated into SAP group (n = 27), UAP group (n = 28), and AMI group
(n = 30). Twenty hospitalized patients with normal coronary angiography were recruited as controls. The
frequency of EMPs, IFN-γ, and IL-4 levels were measured, and the correlation between EMPs and Th1/Th2
cytokine was analyzed. PBMCs isolated from patients with ACS were treated in vitro with EMPs. This was
followed by ﬂow cytometry for Th1/Th2 counts, real-time PCR and western blotting for T-bet and GATA
mRNA and protein expression, and ELISA for IFN-γ, TNF-α, IL-4, and IL-10.
Results: This study proved that the frequency of EMPs was signiﬁcantly increased in ACS patients. There was
a signiﬁcant positive correlation between EMPs and IFN-γ. EMPs could signiﬁcantly upregulate the differ-
entiation and function of Th1 through increasing the expression of T-bet mRNA and protein. Furthermore,
this study also indicated that EMP treatment in vitro could promote the expression of TNF-α, which exerts
adverse effects on the pathogenesis and progression of atherosclerosis.
Conclusions: EMPs may be involved in the immune and inﬂammatory processes that take part in artery
atherosclerosis and that they do so by regulating Th1/Th2 differentiation and function. They may play an
important role in the pathogenesis of coronary atherosclerosis and plaque instability.© 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Coronary atherosclerosis is a chronic immune disease mediated by
CD4+ T lymphocytes and other immune cells [1]. A T-cell inﬁltrate is
always present in atherosclerotic lesions and consists predominantly
of CD4+ cells, which recognize protein antigens presented to them as
fragments by MHC II molecules [2]. After appropriate activation, helper
T cells (Th) differentiate into pro-inﬂammatory Th1 secreting interferon
(IFN)-γ, interleukin (IL)-2 and TNF-α or anti-inﬂammatory Th2 cells
secreting IL-4 and IL-10. Th1 cytokines, such as IFN-γ and IL-2, are pres-
ent in the human plaque and contribute to inﬂammatory effects by ac-
tivating macrophages, endothelial and smooth muscle cells. Therefore,
Th1 cells play a major role in the pathogenesis of atherosclerosis. In
contrast, IL-4, the prototypical anti-inﬂammatory cytokine of theported in part by the research
hina (81160046) and Natural
oad, Qinzhou 535099, Guangxi,
td. All rights reserved.Th2, is not frequently observed in human plaques. Experimental
evidences involved in Th2 are contradictory, with some showing
proatherosclerotic effects and others showing protective effects or
no signiﬁcant effect [3]. The current studies indicate that the out-
come of the atherosclerotic process is partly determined by the bal-
ance between Th1 and Th2 driven responses. Furthermore, Th1/Th2
imbalance is not only involved in the occurrence and development
of coronary atherosclerosis but also closely related to the occurrence
of plaque instability and acute coronary syndrome (ACS) [4].
Recent studies have conﬁrmed that the endothelial microparti-
cles (EMPs), the tiny vesicles released from endothelial cell after ac-
tivation or apoptosis, can indicate the status of endothelial function
and dysfuncton in atherosclerosis and ACS [5]. Mallat et al. showed
that EMPs are signiﬁcantly elevated in patients with ACS compared
with other coronary or non-coronary patients [6]. Bernal-Mizrachi
et al. analyzed the relationships between EMP levels and the degree
of morphological and found that EMPs are correlated positively with
the extent and severity of coronary stenosis at angiography [7,8].
More importantly, because EMPs are effector substances, they can
be involved in inﬂammatory process, blood coagulation, and regula-
tion of vascular function [9]. EMPs may at least partly be responsible
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that circulating EMPs could bind platelets, form aggregates, and be
involved in thrombus formation in patients with acute myocardial in-
farction [10]. EMPs impaired ACh-induced vasorelaxation and nitric
oxide production by aortic rings obtained from Sprague–Dawley rats
in a concentration-dependent manner [11]. In addition, Angelot et al.
[26] conﬁrmed that EMPs speciﬁcally induce plasmacytoid dendritic
cell maturation and production of inﬂammatory cytokines, which
provided the evidence for the involvement of EMPs in immune
modulations.
Collectively these data showed that EMPs may participate in the
occurrence or development of coronary atherosclerosis or in the
development of plaque instability bymodulating immune responses.
However, it remains unclear whether EMPs exert differential effects
on functions of Th1 and Th2 in patients with acute coronary syn-
drome. This study was conducted to explore the relationship be-
tween the plasma EMPs and Th1, Th2 cytokine levels in patients
with coronary heart disease and to investigate the role of EMPs in
the regulation of peripheral blood Th1 and Th2 cells from patients
with ACS. In this way, we attempted to determine the role of EMPs
in the pathogenesis of ACS.
2. Methods
2.1. Reagents and instruments
Human umbilical vein endothelial cell line ECV-304 was obtained from ATCC,
U.S.; improved RPMI1640 medium was obtained from HyClone Laboratories
(U.S.); fetal bovine serum was obtained from Hangzhou Evergreen Biological En-
gineering Materials Co., Ltd., Hangzhou, China; human lymphocyte separation
medium was obtained from Beijing Solai Bao Technology Co., Ltd., Beijing,
China; TNF-α was obtained from PeProtech, U.K.; ﬂuorescein isocyanate (FITC)-
labeled CD42 monoclonal antibody (mAb) and phycoerythrin (PE)-labeled
CD31 mAb were obtained from Proteintech Group, U.S.; standard microparticles
of 0.8 μm or 3.0 μm in diameter were from Duke Co., U.S. The phycoerythrin
green pigment dye 5 (PE-Cy5)-labeled mouse anti-human CD4 mAb, PE-
labeled mouse anti-human IFN-γ mAb, and FITC-labeled mouse antihuman IL-
4 mAb were obtained from Biolegend, U.S. TRNzol-A+ total RNA extraction
reagent was obtained from Beijing Tiangen Co., Ltd., Beijing, China. PCR primers
were synthesized by Shanghai Biological Engineering Co., Ltd., Shanghai, China.
A First-Strand cDNA Synthesis Kit and All-in-One™ qPCR Mix were obtained
fromGeneCopoeia, U.S. T-box expressed in T cells (T-bet), GATA binding protein
3 (GATA-3), and β-actin polyclonal antibody were obtained from Proteintech
Group Company, U.S. An ECL chemiluminescence kit, horseradish peroxidase
(HRP)-labeled goat anti-rabbit IgG, and a DAB staining kit were obtained from
DAKO, Denmark. Human IFN-γ, TNF-α, IL-4, and IL-10 enzyme-linked immuno-
sorbent adsorption (ELISA) quantitation kits were obtained from (R&D, U.S.). An
Epics XL ﬂow cytometer was obtained from Beckman Coulter Inc., U.S. An ABI
Prism 7500 ﬂuorescence quantitative thermal cycler was obtained from ABI,
U.S. A vertical electrophoresis unit, electrophoresis tank, protein membrane
transfer device, and GelDoc2000 gel imaging analysis system were obtained
from Bio-Rad, U.S. The medical X-ray ﬁlm was obtained from Kodak, U.S.
2.2. Patients and control subjects
Twenty-seven patients with stable angina pectoris (SAP), twenty-eight
patients with unstable angina pectoris (UAP), and thirty patients with
acute myocardial infarction (AMI) were selected for this study. Twenty hos-
pitalized patients with normal coronary angiography were recruited as the
control group. All patients were admitted to the Second People's Hospital
of Qinzhou City from January to December, 2011. A diagnosis of coronary
heart disease was made according to WHO diagnostic criteria [12,13]: 1. Stable
angina: the stress-caused sternum or precordial squeezing or tightening pain
or discomfort, which could be alleviated after rest or sublingual nitroglycerin
tablets within 5 min. 2. Unstable angina: New-onset angina, stress-deteriorated
angina, and angina occurring at rest, at least one episode within 48 h before
admission. 3. Acute myocardial infarction: No more than 24 h prior to enroll-
ment, symptoms of myocardial ischemia persisting for more than 30 min,
no relief after rest or taking nitrates, and serum markers of myocardial injury(CK-MB and troponin) exceeding 2-fold of the upper limit of normal. 4. Control
group: chest pain but no ischemic electrocardiographic changes, with normal
coronary angiography. Patients meeting the following criteria were excluded:
infection, malignancy, severe liver and kidney insufﬁciency, connective tissue
disease, endocrine diseases, autoimmune diseases, other heart diseases, such
as myocarditis, endocarditis, rheumatic heart disease, or treatment with anti-
inﬂammatory or immunosuppressant drugs in the past 3 weeks.
All experiments were performed in strict compliance with the 2008
Helsinki Declaration amendment on ethics requirements and in accor-
dance with the Human Trial Guidelines issued by the Medical Ethics
Committee of the Second People's Hospital of Qinzhou City [14]. The
Medical Ethics Committee of the Second People's Hospital of Qinzhou
City approved this study. The study was performed under the supervision
of the ethics committee. Patients provided written informed consent
before joining the study.2.3. Assessment of plasma EMPs
Fresh peripheral vein blood samples (3 ml) were obtained using vacuum
anticoagulant test tubes from patients with AMI or UAP immediately
after admission. The fasting fresh peripheral venous blood samples were
obtained from patients with SAP and from control group patients the morn-
ing after admission. Samples were centrifuged at 160 g for 10 min to pro-
duce platelet-rich plasma and then centrifuged at 1500 g for 6 min for
platelet-poor plasma. Fifty microliters of platelet-poor plasma was mixed
with 0.5 μg of ﬂuorescent-labeled speciﬁc antibodies (anti-CD42-FITC
and anti-CD31-PE, BD Biosciences, U.S.) or mixed with equal amounts of
isotype-control antibodies (MICE IgG1/PE and MICE IgG1/FITC, BD Biosci-
ences, U.S.) After 20 min of incubation at room temperature, 1 ml PBS
was added and the mixture was subjected to ﬂow cytometry (Beckman
Coulter, U.S.), which was completed within 4 h of blood collection. EMPs
were deﬁned as CD31+/CD42− microparticles with diameters under
1.0 μm.2.4. Isolation and in vitro culture of peripheral blood mononuclear cells (PBMCs)
PBMCs were isolated from patients with ACS by Ficoll-Hypaque density
gradient centrifugation. At 37 °C, 5% CO2, the isolated PBMCs (2 × 106/ml)
were cultured in RPMI1640 medium supplemented with 10% fetal bovine
serum, 100 U/ml penicillin, and 100 U/ml streptomycin. The cells were stimu-
lated using EMPs for 48 h at ﬁnal concentrations of 0, 103, 104, 105, 106/ml.2.5. In vitro culture of human umbilical vein endothelial cells (HUVECs)
Cells from human umbilical vein endothelial cell line ECV-304were thawed
and cultured at 37 °C, 5% CO2, in RPMI 1640 medium supplemented with 10%
fetal bovine serum, 100 U/ml penicillin, and 100 U/ml streptomycin. When
the cells reached sub-conﬂuence, they were treated with 0.25% trypsin diges-
tion and then passaged.2.6. In vitro preparation and identiﬁcation of EMPs
As described by Brown et al. [15], EMPswere prepared by culturing HUVECs
(after three passages) for 48 hwith TNF-α at a ﬁnal concentration of 100 ng/ml.
The supernatants were centrifuged at 4300 g for 5 min to remove cells and cell
debris and then at 20,000 g for 2 h at 10 °C. The supernatant was discarded and
the precipitate was washed 2 times with PBS to remove TNF-α residues. The
EMPs were resuspended in PBS. Fifty microliters of EMPs were mixed with
10 μl of FITC-labeled anti-CD42 mAb and PE-labeled anti-CD31 mAb. The
same amount of control antibody was added to another 50 μl of EMPs. After in-
cubation at room temperature for 15 min, the labeled EMPs were washed 2
times and resuspended in 100 μl PBS for ﬂow cytometry. The gating was set
up using standard particleswith diameters of 0.8 μm, and EMPswere quantiﬁed
using the quantitative standard particles with diameters of 3 μm. Before ﬂow
cytometry analysis, EMP samples were mixed with 105 standard microparticles
with diameters of 0.8 μm or with the same number of standard microparticles
with diameters of 3 μm. Twenty thousand standard particles with diameters
of 3 μm were counted and used to calculate the concentrations of EMPs. EMPs
were deﬁned as CD31+/CD42−microparticles with diameters under 1.0 μm.
Table 1
Primes for real-time quantitative PCR.
Gene Primer sequence
T-bet Forward primer 5′-AATGTGACCCAGATGATTGTGC-3′
Reverse primer 5′-GTAAAGATATGCGTGTTGGAAGC-3′
GATA-3 Forward primer 5′-CGAGATGGCACGGGACACTAC-3′
Reverse primer 5′-TTGTGGTGGTCTGACAGTTCGC-3′
β-actin Forward primer 5′-TGACGTGGACATCCGCAAAG-3′
Reverse primer 5′-CTGGAAGGTGGACAGCGAGG-3′
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Two hundred thousand PBMCs cultured in RPMI-1640 medium
supplemented with 10% FBS were stimulated with phorbol esters
(25 ng/ml), ionomycin (1 μg/ml), and monensin (1.7 μg/ml) for 5 h. PE-
CY5-CD4 antibody (5 μl) was added. After incubation at room tempera-
ture for 15 min, the cells were washed 2 times, permeabilized for 10 min
with 500 μl permeabilization reagents, and then incubated with PE-IFN-
γ and FITC-IL-4 mAbs or isotype control antibodies at room temperature
for 15 min. Then a ﬂow cytometry assay was performed.
2.8. Real-time quantitative PCR assay
Total RNA was extracted from in vitro cultured cells after phytohemag-
glutinin (5 ng/ml) stimulation with Trizol and then reverse transcribed to
cDNA. The qPCR reaction system was established. The primers for T-bet,
GATA-3 and an internal reference β-actin were synthesized by Shanghai
Sangon Limited (Shanghai, China) (Table 1). The PCR reaction procedure
was as follows: 95 °C denaturation 10 min; 40 cycles (95 °C, 10 s; annealing,
20S; 72 °C, 31S). The annealing temperature was 58 °C. After ampliﬁcation,
the reaction was slowly heated from 72 °C to 95 °C, to create a PCR product
melting curve. Each specimen was subjected to two PCR reactions. The relative
expression levels of target genes were calculated using the 2−ΔΔCt formula.
2.9. Western blotting
Whole proteins were extracted from in vitro cultured cells after phyto-
hemagglutinin (5 ng/ml) stimulation using protein lysis buffer. The protein
concentration was determined using the Bradford method. After 10% SDS-
PAGE gel electrophoresis, proteins were transferred to PVDF membranes,
which were blocked at room temperature for 1 h. Rabbit anti-human T-bet
or GATA-3 polyclonal antibodies (1:500) were added to the membranes
and incubated at room temperature for 2 h. Mouse anti-human β-actin
monoclonal antibody (1:2000) was used as an internal control. TheTable 2
Basic clinical characteristics of patients.
Characteristics Control
(n = 20)
SAP
(n = 27)
U
(
Age (x ± s, years) 56.6 ± 9.0 60.4 ± 9.9 5
Sex [male (%)] 15(75.0) 21(77.8) 2
Risk factors
Smoking [n (%)] 9 (45.0) 15 (55.6) 1
Hypertension [n (%)] 7 (35.0) 10 (37.0) 1
Diabetes [n (%)] 5 (25.0) 7 (25.9) 6
Dyslipidemia [n (%)] 5 (25.0) 14 (51.9) 1
Medication
β-blockers 4 (20.0) 13 (48.1) 1
ACEI/ARB 7 (35.0) 19 (70.4) 1
CCB 5 (25.0) 8 (29.6) 9
Nitrates 0 (0) 4 (14.8) 6
Statins 7 (35.0) 16 (59.3) 1
HsCRP (mg/l) 1.35 ± 0.37 1.83 ± 0.38 3
SAP = stable angina pectoris; UAP = unstable angina pectoris; AMI = acute myocardial in
antagonist; CCB = calcium antagonists; hsCRP = high-sensitivity C-reactive protein.
⁎ P b 0.001 vs. control or SAP group.membranes were rinsed and the corresponding secondary antibody was
added. After 1 h of additional incubation, ECL radiant agent was added.
The X-ray ﬁlms were exposed in darkroom, then developed and ﬁxed 10–
20 min after exposure. By analyzing the grayscale values of the bands
using Quantity One software, the expression levels of the target gene pro-
teins were quantitated relative to internal control.2.10. Enzyme-linked immunosorbent assay (ELISA)
Fresh peripheral vein blood samples (4 ml) were obtained with vacuum
anticoagulant test tubes from patients with AMI and UAP immediately after
admission. The fasting peripheral vein blood samples were obtained from
patients with SAP or from the control group in the morning after admission.
Blood samples were centrifuged at 3000 g for 15 min. The serawere collected
from the upper layer and stored at −80 °C before use. In in vitro experiments,
PBMCs were stimulated with EMPs, and then stimulatedwith phytohemaggluti-
nin at 5 ng/ml. The cells were cultured at 37 °C, 5% CO2 for 48 h, and the super-
natants were collected. All specimens collected were subjected to ELISA for
assessment of the serum levels of IFN-γ and IL-4 in patients with coronary
heart disease and levels of IFN-γ, TNF-α, IL-4, and IL-10 in cell culture superna-
tants. All ELISAs were performed in accordance with the manufacturers'
instructions.2.11. Statistical analysis
All statistical analyses of the results were performed with SPSS 13.0 soft-
ware. Measurement data are expressed as Mean ± SD. They were analyzed
using one-way ANOVA and SNK when the distribution of data was normal
and the variance indicated of homogeneity. Otherwise, the Kruskal–Wallis
rank sum test was performed, and pairwise comparisonswith Bonferronimeth-
od were used for corrected P value. This was followed by Wilcoxon Rank-Sum
Test. Count data are expressed as frequency and constitute ratio. These were
analyzed using the x2 test. Correlations between variables were tested with
Pearson's correlation analysis. P b 0.05 was considered statistically signiﬁcant.3. Results
3.1. Basic clinical characteristics of patients
Basic clinical characteristics of patients were shown in Table 2. There
were no differences among the groups with respect to age, sex, risk
factors, or use of medication (P N 0.01). In contrast, the high-sensitivity
C-reactive protein (hsCRP) was signiﬁcantly higher in AMI and UAP
groups than that in SAP and control groups (P b 0.001).AP
n = 28)
AMI
(n = 30)
F/x2 P value
9.1 ± 9.6 61.7 ± 9.3 1.254 ns
3(82.1) 24(80.0) 0.403 ns
4 (50.0) 17 (56.7) 0.830 ns
1 (39.3) 12 (40.0) 0.157 ns
(21.4) 9 (30.0) 0.564 ns
2 (42.9) 14 (46.7) 3.674 ns
5 (53.6) 16 (53.3) 6.792 ns
7 (60.7) 21 (70.0) 7.698 ns
(32.1) 9 (30.0) 0.292 ns
(21.4) 7 (23.3) 5.595 ns
8 (64.3) 21 (70.0) 6.589 ns
.12 ± 0.51⁎ 3.23 ± 0.50⁎ 105.973 b0.001
farction; ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor
Fig. 1. The frequency of endothelial microparticles. *P b 0.05 vs. the control; #P b 0.01 vs.
the control; △P b 0.01 vs. stable angina pectoris (SAP); ▲P b 0.05 vs. unstable angina
pectoris (UAP).
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and IL-4
The plasma EMPs were observed by a ﬂow cytometry assay and
the serum concentrations of IFN-γ and IL-4 detected by ELISA.Fig. 2. The correlation of endothelial microparticles (EMPs) and interferon (IFN)-γ and interle
pectoris (SAP), unstable angina pectoris (UAP) and acute myocardial infarction (AMI). *P b 0
IFN-γ. The frequency of EMPs was positively correlated with the serum concentration of IFN
SAP, UAP and AMI. The IL-4 concentrations have no difference in each group (P N 0.05); D. Pers
centration of IL-4 (r = −0.088, P = 0.374).Furthermore, we performed a correlation analysis to determine the
relationship between the plasma EMPs and serum concentrations
of IFN-γ and IL-4. We obtained that EMP levels in plasma were
signiﬁcantly increased in UAP and AMI groups compared to the con-
trol and SAP groups (P b 0.01). The plasma EMP levels in patients
with SAP were also signiﬁcantly higher than that in the control
group, and plasma EMP levels in patients with AMI were signiﬁcant-
ly higher than that in patients with UAP (all P b 0.05) (Fig. 1).
The result of Pearson's correlation analysis showed that plasma
EMPs had a signiﬁcant positive correlation with IFN-γ (r = 0.795,
P b 0.001) but no correlation with IL-4 (r = −0.088, P = 0.374)
(Fig. 2).3.3. Effect of EMPs on the frequency of Th1 and Th2 lymphocytes in cultured
PBMCs from patients with ACS
To verify whether EMPs could exert differential effects on Th1 and
Th2, we performed experiments on PBMCs cultivated in vitro with the
EMPs. The effect of EMPs on the frequency of Th1 and Th2 lymphocytes
in cultured PBMCs are shown in Fig. 3. The percentage of Th1 cells was
gradually increased as the concentration of EMPs increased (104/ml to
106/ml). The percentage of Th1 cells was signiﬁcantly higher in 104 toukin (IL)-4. A. Serum concentration of IFN-γ in controls and patients with stable angina
.05 vs. control; #P b 0.01 vs. SAP; △P b 0.05 vs. UAP; B. Person correlation of EMPs and
-γ (r = 0.795, P b 0.001); C. Serum concentration of IL-4 in controls and patients with
on correlation of EMPs and IL-4. The frequency of EMPs did not correlate with serum con-
Fig. 3. Effect of endothelialmicroparticles on the frequency of Th (T helper)-1 and Th2 lymphocytes in vitro. A. Representation of intracellular cytokine staining of Th1 and Th2 cells. B. FACS
results of the percentage of Th1 cells; *P b 0.01 vs. 0/ml and 103/ml; #P b 0.01 vs. 104/ml;△P b 0.01 vs. 105/ml; C. FACS results of the percentage of Th2 cells. Th2 frequencies showed no
differences among these groups (P N 0.05).
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ever, no difference was found in the percentage of Th2 cells among the
groups (P N 0.05).3.4. Effect of EMPs on the expression of T-bet and GATA-3 in PBMCs from
patients with ACS
To further assess themechanism by which T-bet and GATA-3 are in-
volved in the effect of EMPs on differential and functions of Th1 and Th2.
we performed real-time quantitative PCR and Western blotting to as-
sess the expression of T-bet andGATA-3. EMPs signiﬁcantly upregulated
the mRNA and protein level of T-bet. The T-bet mRNA and protein
expression in cultured PBMCs in vitro was gradually increased with
increases in the concentration of EMPs (104/ml to 106/ml). The T-betmRNA and protein expression was signiﬁcantly higher in 104/ml to
106/ml groups than that in 0/ml and 103/ml groups (all P b 0.001)
(Figs. 4A and 5A). However, EMPs did not upregulate the mRNA and
protein level of GATA-3 (all P N 0.05) (Figs. 4B and 5B). These results
suggested that EMPs induced the expression of T-bet, but not GATA-3.3.5. Effect of EMPs on the concentrations of Th1, Th2 cytokines in cultured
PBMCs from patients with ACS
We examined the effect of EMPs on the concentrations of Th1, Th2
cytokines in cultured PBMCs from patients with ACS. EMPs signiﬁcantly
increased the concentrations of IFN-γ and TNF-α in a concentration-
dependent manner in the supernatants of cultured PBMCs in vitro (104
to 106/ml). The concentrations of IFN-γ and TNF-α were signiﬁcantly
Fig. 4. Effect of endothelial microparticles on the expression of T-bet and GATA-3mRNA in vitro. ThemRNA levels of T-bet and GATA-3 weremeasured by real-time quantitative PCR. The
relative expression levels of target geneswere calculated using the 2−ΔΔCt formula. A. The expression of T-betmRNA; *P b 0.001 vs. 0/ml and 103/ml; #P b 0.001 vs. 104/ml;△P b 0.001 vs.
105/ml; B. EMPs had no signiﬁcant impact on the level of GATA-3 mRNA (P N 0.05).
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(all P b 0.01). However, no difference in IL-4 and IL-10 concentrations
was observed among the groups (all P N 0.05) (Fig. 6). These ﬁndings
suggested that EMPs induced the expression of IFN-γ and TNF-α, but
not IL-4 and IL-10.
4. Discussion
Under physiological conditions, vascular endothelial cells inhibit
adhesion and blood coagulation and maintained vascular tension,
but they have only a weak secretory function [16]. Upon activationFig. 5.Effect of endothelialmicroparticles on the expression of T-bet andGATA-3protein in vitro.
was normalized against β-actin. A. The expression of T-bet and GATA-3 protein; *P b 0.001 vs. 0
GATA-3 protein among these groups showed no signiﬁcant differences (P N 0.05); C. Represenor apoptosis, endothelial cells release small vesicles called EMPs. In
this way, plasma levels of EMPs can be used to assess the functional
and dysfunctional status of endothelial cells [5]. The circulating
blood levels of EMPs not only reﬂected the extent of vascular lesions
in coronary heart disease but are also associated with plaque insta-
bility, which can be used as a marker of plaque instability [9].
In this study, we used the methods described by Brown et al. to pre-
pare EMPs from TNF-α-stimulated HUVECs [15]. The results showed
that HUVECs could be activated and impaired by TNF-α, producing
large amount of EMPs. This once again conﬁrmed that EMPs can be
used asmarkers of the evaluation of endothelial injury and dysfunction.Theprotein levels of T-bet andGATA-3weremeasuredbywesternblot. Protein expression
/ml and 103/ml; #P b 0.001 vs. 104/ml;△P b 0.001 vs. 105/ml; B. The relative expression of
tative electropherogram of T-bet and GATA-3 protein.
Fig. 6. Effect of endothelial microparticles on the concentrations of cytokines in vitro. The concentrations of cytokines were assayed by speciﬁc enzyme-linked immunosorbent assay
(ELISA). A. The expression of Th1 cytokine interferon (IFN)-γ; *P b 0.01 vs. 0/ml and 103/ml; #P b 0.01 vs. 104/ml;△P b 0.01 vs. 105/ml; B. The expression of Th1 cytokine tumor necrosis
factor (TNF)-α; *P b 0.01 vs. 0/ml and 103/ml; #P b 0.01 vs. 104/ml;△P b 0.01 vs. 105/ml; Th2 cytokines interleukin (IL)-4 and IL-10 showedno signiﬁcant differences among these groups
(P N 0.05).
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tory responses. They are often accompanied by substantial elevation of a
variety of inﬂammatory cytokines such as TNF-α, IL-1, and IL-6 [17,18].
This can further aggravate endothelial dysfunction, elevating peripheral
blood EMP level in patients with ACS.
Coronary atherosclerosis is the major pathological basis of coronary
heart disease. Atherosclerosis is a chronic inﬂammatory response and
immune disease. Various inﬂammatory and immune cells, such as
monocytes/macrophages, dendritic cells, and T lymphocytes and their
effector molecules are both involved in the development of coronary
atherosclerotic plaques and closely related to coronary atherosclerotic
plaque instability [1]. Studies have shown that large numbers of T lym-
phocytes are present in atherosclerotic plaques, mainly Th1 cells, which
produce the cytokines IFN-γ, TNF-α, IL-2, and IL-12. Th2 cells, which
produce IL-4 and IL-10, are less common in these plaques [19]. It has
also been shown that Th1 cells accelerate the process of atherosclerosis,
while Th2 cells may slow it [20]. Clinical studies have shown that Th1
cells are the major activated T lymphocytes in ACS. In ACS vulnerable
plaques, IFN-γ produces by a large number of activated T lymphocytes
inhibits smoothmuscle proliferation, induces the production of collage-
nase, and degrades and weakens the ﬁbrous cap. This renders plaques
more likely to rupture, causing ACS [21]. The excessive degradation of
ﬁbrous cap collagen is the most important cause of plaque instability
and vulnerability. The degradation of collagen requires matrix metallo-
proteinases (MMPs) [22]. Inﬂammatory cytokines can stimulate the
secretion of MMPs, rendering the plaques unstable. Studies have
shown that vascular smooth muscle cells normally express very
low levels of MMP-1 and MMP-2. Upon stimulation by TNF-α andIL-1, the synthesis and secretion of MMP-1 are increased, MMP-2
and MMP-9 are converted from their zymogen forms to their active
forms, and the synthesis and secretion of MMP-3 begin. This leads
to increased degradation of extracellular matrix and to plaque
instability and fragility [23,24].
Our study showed that the serum level of EMPs in patients with
coronary heart disease was signiﬁcantly higher than in control pa-
tients, suggesting that EMP levels reﬂect the degree of endothelial
dysfunction in patients with coronary heart disease. The plasma
levels of EMPs in these patients were also signiﬁcantly higher than
in patients with SAP, suggesting that EMPs are closely associated
with atherosclerotic plaque stability in patients with coronary
heart disease, and can be used as markers for the evaluation of
plaque stability.
Our study also showed that the EMPs in the plasma of patients
with coronary heart disease had a signiﬁcant positive correlation
with the level of Th1-type cytokines IFN-γ but no signiﬁcant correla-
tion with the level of Th2 cytokine IL-4. Considering the close
relationship between increased IFN-γ levels and the coronary ath-
erosclerotic plaque inﬂammatory response, the EMP level, which is
closely related to the level of IFN-γ, may also to some extent reﬂect
the degree of plaque inﬂammation. The fact that plaque formation
had no signiﬁcant correlation with antagonistic cytokines suggested
that there was no signiﬁcant correlation between these cytokines
and the production of EMPs. The abnormal secretion of cytokines
caused by Th1 and Th2 imbalance and the resulting plaque inﬂam-
mation and instability may be important to the increased generation
of EMPs.
5403Y. Lu et al. / International Journal of Cardiology 168 (2013) 5396–5404Recent studies have conﬁrmed that EMPs can affect inﬂamma-
tion, blood coagulation, and vascular function and are closely related
to the occurrence of cardiovascular disease [25]. EMPs released from
endothelial cells carry a variety of biologically active substances, and
their function is closely related to that of the source cells. They
mediate inﬂammatory responses and cell signal transduction and
exertion [11,26]. It has been reported that EMPs extracted from
the peripheral blood of patients with myocardial infarction can
selectively impair endothelial cell nitric oxide signal transduction
pathways, so causing endothelial dysfunction [11]. The EMPs are
also involved in blood coagulation. This is because EMPs carry
von Willebrand factor on their surface, which can promote platelet
aggregation and thrombosis [27]. EMPs can also promote the gener-
ation of adhesion molecules and so promote the adhesion of inﬂam-
matory cells and endothelial cells [8]. EMPs also play a role in the
regulation of immune functions [26]. In view of the close
relationship between EMPs and coronary heart disease, there may
exist an interaction between circulating EMPs and inﬂammatory
cytokines in patients with coronary heart disease. EMPs are inﬂam-
matory mediators, so they may act on Th1 and Th2 cells and may
be involved in the occurrence and development of coronary athero-
sclerosis and plaque instability. To conﬁrm this hypothesis, we have
tested the effects of in vitro-generated EMPs on Th1 and Th2 cell
differentiation and function. The results showed that EMP stimula-
tion up-regulated Th1 cell transcription factor T-beta mRNA and
protein expression and signiﬁcantly increased the production of
Th1 cytokines IFN-γ and TNF-α. However, PBMCs intervention with
EMPs did not result in any signiﬁcant increase in the number of Th2
cells, nor the expression of cell activation transcription factor GATA-3
mRNA and protein. The concentrations of the key cytokines IL-4 and
of IL-10 did not change signiﬁcantly. In this way, the overall effect of
EMPs in patients with ACS was found to be to promote the differentia-
tion of peripheral blood CD4+ T lymphocytes toward Th1 and to in-
crease the expression of Th1 cytokines. However, no signiﬁcant effect
on Th2 differentiation or function was observed. In this way, EMPs
may not only be biomarkers of endothelial dysfunction in ACS patients
with plaque instability but may also directly induce Th1 and Th2 imbal-
ances and so foster plaque formation and instability.
T-bet and GATA-3 are important transcription factors that regu-
late the differentiation of T cells into Th1 and Th2, respectively. The
previous studies have shown that the transcription factor T-bet
expressed exclusively in Th1 cells is central to Th1 differentiation,
resulting in production of Th1 cytokines and selective suppression
of Th2 cytokines [28,29]. GATA-3 was ﬁrst described as a Th2 speciﬁc
transcription factor, and it plays an important role in the control of
Th2 cells differentiation [30]. In the present study, EMPs exhibited
an excellent ability to signiﬁcantly up-regulate the expression of T-
bet in vitro. It suggests that EMPs promote Th1 cytokines production
and Th1 cells differentiation in PBMCs is mediated through the in-
creased induction of T-bet. It is interesting that although PBMCs
have higher expression levels of IFN-γ following stimulation with
EMPs, GATA-3 expression and Th2 cells differentiation were not
signiﬁcantly different between the groups. It suggests that GATA-3
expression might play a less crucial role in the induction of Th2
responses to EMP stimulation. Thus, PBMCs responses in EMP stimu-
lation are controlled at the transcriptional level by the expression
patterns of the transcription factor T-bet.
Our preliminary experiments showed that stimulation with EMPs
at 0–103/ml had no effect on Th1 and Th2 cell differentiation or func-
tion. We did not establish 10/ml or 102/ml EMP stimulation groups
in our study. We used 106/ml as the maximum stimulation EMP
concentration. At this concentration, EMPs were more potent in in-
ducing Th1 differentiation and activation than at 105/ml. However,
106/ml may not be the most effective concentration for the induction
of Th1 cell differentiation or the regulation of their function. Higher
concentrations of EMPs may generate more visible effects. However,according to the results of previous studies, 106/ml is closer to the
actual concentration of EMPs in the circulating blood of patients
with ACS [31]. For this reason, we did not use a higher concentration
of EMPs. Our study was a small-scale, randomized, non-blinded
case–control study. Although all baseline values were comparable
among the groups, these results may still be affected by a variety
of interfering factors, leading to bias. A large-scale randomized con-
trolled trial must be performed to conﬁrm our ﬁndings.
In summary, EMPs participate in the regulation of Th1 cells, mainly
by inﬂuencing Th1 cell activation and secretion of cytokines, which en-
hances the CD4+ T-lymphocyte bias in Th1 cell differentiation and that
this bias is a consequence of the up-regulated expression of T-bet. The
Th1 and Th2 imbalance caused by EMPsmay be involved in the immune
and inﬂammatory processes associated with atherosclerosis in ACS
patients, and it may play an important role in atherosclerosis during
the occurrence, development, and transformation of plaques from sta-
ble to unstable.
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